Serious Adverse Events Among SPRINT Trial Participants Taking Statins at Baseline

ConclusionsIn SPRINT, generally statin use was not associated with increased risk of reporting SAEs. Only statin use by higher risk patients was associated with more overall SAEs. Confounding by clinical CVD and the polytherapy of intensive BP management may explain this.
Source: Drugs in R&D - Category: Drugs & Pharmacology Source Type: research